Search filters

Filters
Clear All

Phase

  • 1
  • 5
  • 3
  • 11
  • 10
  • 11

Found 11 Multiple Myeloma trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
The objective of this exploratory observational cohort study is to obtain blood samples - and in some cases, bone marrow aspirate samples - from patients with multiple myeloma for study in the laboratory.
99 years or below
All genders
Phase 1
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …
 PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1
18 years - 99 years
All genders
Phase 1
This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.
99 years or below
All genders
Phase 2
The main purpose of this study is to investigate the use of a new, experimental drug called JNJ-68284528 in subjects with multiple myeloma.
99 years or below
All genders
Phase 1
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
99 years or below
All genders
Phase 1
The research study is being conducted to understand the effects of tasquinimod, an experimental medication, on patients with myeloma. Eligibile subject have multiple myeloma that has been previously treated and is now in need of additional treatment. Part 1 of this study evaluates tasquinimod alone. Part 2 of this study …
99 years or below
All genders
Phase 1
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.
99 years or below
All genders
Phase 2
The purpose of this study is to test the safety of an experimental drug CC-220, alone and in combination with other treatments. The study is also designed to define the appropriate dose for further testing of the study drug and these experimental combinations.
1 - 10 of 11